SQ 32547
SQ 32547 is a dihydropyridine calcium channel inhibitor with antihypertensive and anti-ischemic activities. SQ 32547 modulates sarcolemmal voltage-dependent calcium channels to inhibit calcium influx, and exerts direct anti-ischemic activity by suppressing myocardial contracture formation and reducing lactate dehydrogenase (LDH) release. SQ 32547 can be used in research related to hypertension, angina pectoris and neurogenic inflammation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 135100-65-1
- Formel: C29H32ClF4N3O4S
- Molecular Weight:630.09
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
Calcium Channel |
In Vitro
SQ 32547 potently inhibits KCl-induced contraction of various isolated smooth muscle preparations, with its IC50 values ranging from 4.2 nM (canine saphenous vein) to 320 nM (rat vas deferens)[2].
SQ 32547 binds irreversibly to calcium channels in vascular smooth muscle, and the drug cannot be removed by tissue elution[2].
SQ 32547 (10-300 nM; administered before ischemia) inhibits myocardial contracture and reduces lactate dehydrogenase (LDH) leakage in a concentration-dependent manner in isolated globally ischemic rat hearts, while the degree of myocardial depression gradually increases with rising concentrations[2].
SQ 32547 exerts a cardiodepressive effect on isolated rat hearts, and this effect cannot be washed out within 60 minutes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 135100-65-1
-
Molecular Weight 630.09
-
Formel C29H32ClF4N3O4S
-
SMILES
FC(C=C1)=CC=C1CN(CC2)CCC2OC(N3[C@H](C4=C(C=CC=C4)C(F)(F)F)C(C(OC(C)C)=O)=C(NC3=S)C)=O.Cl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- SQ 32547
- 135100-65-1
- SQ32547
- SQ-32547
- Calcium Channel
- dihydropyrimidine calcium channel inhibitor
- irreversible binding property
- high lipophilicity
- rat aorta
- isolated guinea pig ileum
- rat vas deferens
- swine carotid artery
- swine LAD artery
- global ischemic rat heart
- pacing-induced ischemic canine model
- stable angina
- myocardial ischemia
- myocardial contracture suppression
- LDH
- Inhibitor
- inhibitor
- inhibit